Document:

f10sb12gex10ii_immunobtic.htm

    Exhibit 10.2

     

    NON-EXCLUSIVE
      PATENT LICENSE AGREEMENT

     

    This
      Non-exclusive Patent License Agreement entered into this 1st day of September,
      2007, by and between ImmunoBiotics, Inc., a corporation organized under the
      laws
      of the State of Florida, having its principal office at 511 NE 94th Street,
      Building 2, MiamiShores, Florida 33138, hereinafter referred to as "Licensor,"
      and SYNORx, Inc., a corporation organized under the laws of the State of Nevada,
      having its principal office at 1060 Calle Negocio, Suite B, San Clemente,
      California 92673, hereinafter referred to as "Licensee."

     

    RECITALS

     

    WHEREAS,
      Licensor is the owner of the following intellectual property: United States
      Patent number 6,774,142 entitled "Inhibition by 3-Deoxyflavonoids of
      T-Lyrnphocyte Activation and Therapies Related Thereto", hereinafter "The
      Patent"; and

     

    WHEREAS,
      Licensee is desirous of researching, developing, marketing, distributing, and
      selling Luteolin and related bioflavonoid-based products under The Patent;
      and

     

    WHEREAS,
      Licensor is willing to grant a Non-exclusive License to Licensee to research,
      develop, markets distribute, and sell Luteolin and related bioflavonoid-based
      products covered by The Patent.

     

    NOW
      THEREFORE, the parties agree as follows:

     

    1.  Licensor
      hereby grants a
      Non-exclusive License to Licensee. This License will grant Licensee all rights
      provided under The Patent.

     

    2.  The
      initial term of the
      Exclusive License shall be Five (5) consecutive years following the date of
      this
      agreement, at which time the Licensee shall have the option to renew at Five
      (5)
      year intervals through the effective dates of the patents, provided that
      licensee is compliant with ALL terms of this agreement and any future agreements
      with Licensor.

     

    3.  In
      consideration for
the Non-exclusive Patent License Agreement, Licensee shall manufacture
      and deliver to Licensor Five Thousand (5,000) bottles of 10 mg LutiMax tablets,
      bottled and labeled as directed by Licensor. Label copy and lables will
      be provided by Licensor. In addition to the manufacture and delivery of the
      5,000 bottles of LutiMax 10 mg tablets, Licensee will pay a royalty of Five
      Percent (5%) of net sales of products sold by Licensee that are covered by
      the
      Patent for the first Five Hundred Thousand $500,000 in sales per year, Seven
      and
      One-Half Percent (7.5%) of net sales per year from Five Hundred Thousand to
      One
      Million dollars ($500,000 to $1,000,000) in sales, and for net sales exceeding
      One Million Dollars ($1,000,000) per year, Licensee will pay Ten
      Percent (10%) of net sales. Licensee shall pay to Licensor annually a minimum
      earned royalty of Ten Thousand Dollars ($10,000.00). The payments of the
      royalties or minimum annual royalty payment will be paid quarterly within 30
      days of completion of each quarter beginning the effective date of this
      Non­-exclusive Patent License Agreement.

    

     

    
      
        
        

      

      
        Page
          1

        
          

        

      

      
        
        

      

    

    

    

          
      4.  Licensee
      shall keep suitable records of sales hereunder and to furnish to Licensor a
      quarterly and annual summary report giving the amount of product manufactured
      or
      sold by Licensee under The Patent, and to accompany such report with a payment
      of royalties accrued hereunder. Royalty payments shall be made payable to
      "ImmunoBiotios, Inc. and wired in US funds to the Licensor's designated bank
      account. To enable Licensor to verify the accuracy of such reports, Licensee
      agrees to permit Licensor's accountant to inspect its pertinent records during
      reasonable business hours upon reasonable notice to Licensee. Licensor shall
      also have the right during normal business hours to inspect the premises where
      SYNORx, inc.'s products are packaged, stored, marketed, or sold for the
      purposes of verifying royalties due and the handling of quality
      control.

     

          
      5.  Licensor
      believes that Luteolin and related bioflavonoid-based products and the
      compositions protected under The Patent are suitable for United States sale
      and
      use; however, it makes no representation in this regard. Licensor shall not
      have
      any responsibility to Licensee in the event Luteolin or the products
      manufactured under The Patent do not perform satisfactorily.

     

          
      6.  Licensee
      shall maintain the quality of Luteolin, LutiMax, and all products sold
      under this Agreement as required by the minimum standards for Dietary
      Supplements and Drugs (if such product is sold as a drug) in the United States.
      Licensor reserves the right to inspect the quality of all products sold under
      this Agreement to ensure that the quality is as required

     

          
      7.  Licensee
      agrees to Licensor harmless from any liability or expense in connection
      with its marketing, sales, or use of Luteolin or Luteolin-based
      products.

     

           
      8.  The
      name
      of Licensor shall not be used in advertising without the express written
      permission of Licensor.

     

           
      9.  In
      the
      event that protection rights to The Patent are infringed by a third party,
      Licensor shall have the first opportunity to sue for infringement and to recover
      and retain any and all damages after paying Licensee its royalties based upon
      the infringers sales. In the event that Licensor does not desire to sue for
      any
      infringement, the Licensee thereafter will have the right to sue for
      infringement and retain all damages recovered there from. The party bringing
      the
      suit shall be responsible for all of the costs of the suit unless there is
      a
      further agreement between Licensor and Licensee in this regard.

     

           
      10.  This License
      shall not be assignable by Licensee without the prior written consent of
      Licensor, which consent shall not be unreasonably withheld.

     

           
      11.  Licensor may,
at its option,
      terminate this agreement by written notice to
      Licensees if Licensee shall default in:

     

                   
      a.         The payment of any royalties
      required to be paid by Licensee to Licensor hereunder; or

    

     

    
      
        
        

      

      
        Page
          2

        
          

        

      

      
        
        

      

    

     

    b.        The
      making and submission of any reports required hereunder; or

     

    c.        
      If
      such
      default shall continue for a period of thirty (30) days after Licensor shall
      have given to Licehsee a written notice of such default;

     

    12.  Failure
      or delay by Licensor to exercise its right of termination hereunder by reason
      of
      any default by Licensee in carrying out any obligation imposed upon it by this
      Agreement shall not operate to prejudice Licensor's right of termination for
      any
      other subsequent default by Licensee.

     

    13.  Unless
      sooner terminated in accordance with its terms, this Agreement shall continue
      through the life of Patents and any renewals thereof provided, however that
      if
      the Patent Protection is held to be invalid by a court having jurisdiction
      in a
      decision which has become final, un-appealable and un-reviewable, the Licensee's
      obligation to pay future royalties and patent maintenance fees shall
cease.

     

    14.  Licensee
      may terminate the License granted by this Agreement, provided Licensee shall
      not
      be in default hereafter by giving Licensor ninety (90) days written notice
      of
      its intention to do so. If such notice is given, then upon the expiration of
      such ninety (90) days the termination shall become effective; but such
      termination shall not operate to relieve Licensee from its obligation to pay
      royalties or to satisfy and other obligations accrued hereunder prior to the
      data of such termination. Upon termination of this Agreement, all of the
      licensed rights shall automatically revert to Licensor.

     

    15.  Licensee
      shall provide Licensor with detailed information on the performance of Luteolin,
      particularly any information which might reflect adversely on ImmunoBiotics,
      Inc. or the use of Luteolin or Luteolin-based products.

     

    16.  Licensor
      retains the
      right to freely research, manufacture, market, sell and distribute Luteolin
      products and products covered by The Patent for all purposes and does
      not forgo any rights of its own under The Patent.

     

    17.  This
      agreement shall be governed and construed in accordance with the laws of the
      State of Florida, the United States of America, and any dispute, controversy
      or
      claim arising out of or relating to this Agreement shall be brought and decided
      in the courts of MiamiDace County, Florida or the United States Federal Courts
      in Florida, and the parties agree to accept service of process by registered
      mail, and waive any jurisdictional or venue defenses otherwise
      available.

     

    18.  This
      Agreement represents the entire Agreement between the partieswith respect to
      the
      subject matter hereof, and supersedes all prior agreements between the parties
      on this subject, and may be amended only by a written instrument or instruments
      signed on behalf of the parties hereto.

     

    19.  If
      any part of this
      Non-Exclusive Patent License Agreement is decided by a court of law to be
      unlawful, the remaining parts of this PATENT Non-Exclusive Patent License
      Agreement are enforceable and intact to be deemed as lawful and
      binding.

    

     

    
      
        
        

      

      
        Page
          3

        
          

        

      

      
        
        

      

    

     

    IN
      WITNES
      WHEREOF, the parties have caused this Agreement to be executed as of
      the
      day and year first above written..

     

    LICENSOR:                                                          LICENSEE:

    ImmunoBiotics,
      Inc.                                         
 SYNORx, Inc.

     

    By:
      /s/Thomas P.
      Lahey                                    By:
      /s/Thomas P. Lahey

    Thomas
      P.
      Lahey                                               
Thomas P. Lahey 

    Title:
      President                                                   
Title: President     

     

     

     

    Page
      4ex10_2.htm

     

    Exhibit
      10.2

     

     

    THE
      2007/2008 NON-QUALIFIED STOCK COMPENSATION PLAN

    

    OF

    

    RED
      REEF LABORATORIES
      INTERNATIONAL, INC.

     

     

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

     

    THE
      2007/2008 NON-QUALIFIED STOCK COMPENSATION PLAN

    OF

     RED
      REEF LABORATORIES INTERNATIONAL, INC.

    

    1. Purpose
      of Plan

    

    1.1 This
      2007/2008 Non-Qualified Stock Compensation Plan (the
“Plan”) of  Red Reef Laboratories International, Inc., a Florida
      corporation (the “Company”), for employees, directors, officers consultants,
      advisors and other persons associated with the Company, is intended to advance
      the best interests of the Company by providing those persons who have a
      substantial responsibility for its management and growth with additional
      incentive and by increasing their proprietary interest in the success of the
      Company, thereby encouraging them to maintain their relationships with the
      Company. Further, the availability and offering of stock options and Common
      Stock under the Plan supports and increases the Company's ability to attract
      and
      retain individuals of exceptional talent upon whom, in large measure, the
      sustained progress, growth and profitability of the Company
      depends.

    

    2. Definitions

    

    2.1 For
      Plan purposes, except where the context might clearly indicate otherwise, the
      following terms shall have the meanings set forth below:

    

    “Board”
      shall mean the Board of Directors of the Company.

    

    “Committee”
      shall mean the Compensation Committee, or such other committee appointed by
      the
      Board, which shall be designated by the Board to administer the Plan, or the
      Board if no committees have been established. The Committee shall be composed
      of
two or more persons as from time to time are appointed to serve by the
      Board.

    

    “Common
      Shares” shall mean the Company's Common Shares, $.001 par value per share, or,
      in the event that the outstanding Common Shares are hereafter changed into
      or
      exchanged for different shares of securities of the Company, such other shares
      or securities.

    

    “Company”
      shall mean Red Reef Laboratories International, Inc., a Florida
      Corporation, and any parent or subsidiary corporation of Red Reef Laboratories
      International, Inc., as such terms are defined in Sections 425(e) and 425(f),
      respectively, of the Code.

    

    “Fair
      Market Value” shall mean, with respect to the date a given stock option is
      granted or exercised, the average of the highest and lowest reported sales
      prices of the Common Shares, as reported by such responsible reporting service
      as the Committee may select, or if there were not transactions in the Common
      Shares on such day, then the last preceding day on which transactions took
      place. The above withstanding, the Committee may determine the Fair Market
      Value
      in such other manner as it may deem more equitable for Plan purposes or as
      is
      required by applicable laws or regulations.

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

    “Optionee”
      shall mean an employee of the company who has been granted one or more Stock
      Options under the Plan.

    

    “Common
      Stock” shall mean shares of Common Stock which are issued by the Company
      pursuant to Section 5, below.

    “Common
      Stockholder” means the employee of, consultant to, or
      director of the Company or other person to whom shares of Common Stock are
      issued pursuant to this Plan.

    

    “Common
      Stock Agreement” means an agreement executed by a Common Stockholder and the
      Company as contemplated by Section 5, below, which imposes on the shares of
      Common Stock held by the Common Stockholder such restrictions as the Board
      or
      Committee deem appropriate.

    

    “Stock
      Option” or “Non-Qualified Stock Option” or “NQSO” shall mean a stock option
      granted pursuant to the terms of the Plan.

    

    “Stock
      Option Agreement” shall mean the agreement between the Company and the Optionee
      under which the Optionee may purchase Common Shares hereunder.

    

    3. Administration
      of the Plan

    

    3.1 The
      Committee shall administer the Plan and accordingly, it shall have full power
      to
      grant Stock Options and Common Stock, construe and interpret the Plan, establish
      rules and regulations and perform all other acts, including the delegation
      of
      administrative responsibilities, it believes reasonable and proper.

    

    3.2 The
      determination of those eligible to receive Stock Options and Common Stock,
      and
      the amount, type and timing of each grant and the terms and conditions of the
      respective stock option agreements and Common Stock Agreements shall rest in
      the
      sole discretion of the Committee, subject to the provisions of the
      Plan.

    

    3.3 The
      Committee may cancel any Stock Options awarded under the Plan if an Optionee
      conducts himself in a manner which the Committee determines to be inimical
      to
      the best interest of the Company, as set forth more fully in paragraph 8 of
      Article 11 of the Plan.

    

    3.4 The
      Board, or the Committee, may correct any defect, supply any omission or
      reconcile any inconsistency in the Plan, or in any granted Stock Option, in
      the
      manner and to the extent it shall deem necessary to carry it into
      effect.

    

    3.5 Any
      decision made, or action taken, by the Committee or the Board arising out of
      or
      in connection with the interpretation and administration of the Plan shall
      be
      final and conclusive.

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

    3.6 Meetings
      of the Committee shall be held at such times and places as shall be determined
      by the Committee. A majority of the members of the Committee shall constitute
      a
      quorum for the transaction of business, and the vote of a majority of those
      members present at any meeting shall decide any question brought before that
      meeting. In addition, the Committee may take any action otherwise proper under
      the Plan by the affirmative vote, taken without a meeting, of a majority of
      its
      members.

    

    3.7 No
      member of the Committee shall be liable for any act or omission of any other
      member of the Committee or for any act or omission on his own part, including,
      but not limited to, the exercise of any power or discretion given to him under
      the Plan, except those resulting from his own gross negligence or willful
      misconduct.

    

    3.8 The
      Company, through its management, shall supply full and timely information to
      the
      Committee on all matters relating to the eligibility of Optionees, their duties
      and performance, and current information on any Optionee's death, retirement,
      disability or other termination of association with the Company, and such other
      pertinent information as the Committee may require. The Company shall furnish
      the Committee with such clerical and other assistance as is necessary in the
      performance of its duties hereunder.

    

    4. Shares
      Subject to the Plan

    

    4.1 The
      total number of shares of the Company available for grants of Stock Options
      and
      Common Stock under the Plan shall be 5,000,000 Common Shares, subject to
      adjustment in accordance with Article 7 of the Plan, which shares may be either
      authorized but unissued or reacquired Common Shares of the Company.

    

    4.2 If
      a Stock Option or portion thereof shall expire or terminate for any reason
      without having been exercised in full, the unpurchased shares covered by such
      NQSO shall be available for future grants of Stock Options.

    

    5. Award
      Of Common Stock

    

    5.1 The
      Board or Committee from time to time, in its absolute discretion, may (a) award
      Common Stock to employees of, consultants to, and directors of the Company,
      and
      such other persons as the Board or Committee may select, and (b) permit Holders
      of Options to exercise such Options prior to full vesting therein and hold
      the
      Common Shares issued upon exercise of the Option as Common Stock. In either
      such
      event, the owner of such Common Stock shall hold such stock subject to such
      vesting schedule as the Board or Committee may impose or such vesting schedule
      to which the Option was subject, as determined in the discretion of the Board
      or
      Committee.

    

    5.2 Common
      Stock shall be issued only pursuant to a Common Stock Agreement, which shall
      be
      executed by the Common Stockholder and the Company and which shall contain
      such
      terms and conditions as the Board or Committee shall determine consistent with
      this Plan, including such restrictions on transfer as are imposed by the Common
      Stock Agreement.

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

     

    5.3 Upon
      delivery of the shares of Common Stock to the Common Stockholder, below, the
      Common Stockholder shall have, unless otherwise provided by the Board or
      Committee, all the rights of a stockholder with respect to said shares, subject
      to the restrictions in the Common Stock Agreement, including the right to
      receive all dividends and other distributions paid or made with respect to
      the
      Common Stock.

    

    5.4. Notwithstanding
      anything in this Plan or any Common Stock Agreement to the contrary, no Common
      Stockholders may sell or otherwise transfer, whether or not for value, any
      of
      the Common Stock prior to the date on which the Common Stockholder is vested
      therein.

    

    5.5 All
      shares of Common Stock issued under this Plan (including any shares of Common
      Stock and other securities issued with respect to the shares of Common Stock
      as
      a result of stock dividends, stock splits or similar changes in the capital
      structure of the Company) shall be subject to such restrictions as the Board
      or
      Committee shall provide, which restrictions may include, without limitation,
      restrictions concerning voting rights, transferability of the Common Stock
      and
      restrictions based on duration of employment with the Company, Company
      performance and individual performance; provided that the Board or Committee
      may, on such terms and conditions as it may determine to be appropriate, remove
      any or all of such restric-tions. Common Stock may not be sold or encumbered
      until all applicable restrictions have terminated or expire. The restrictions,
      if any, imposed by the Board or Committee or the Board under this Section 5
      need
      not be identical for all Common Stock and the imposition of any restrictions
      with respect to any Common Stock shall not require the imposition of the same
      or
      any other restrictions with respect to any other Common Stock.

    

    5.6 Each
      Common Stock Agreement shall provide that the Company shall have the right
      to
      repurchase from the Common Stockholder the unvested Common Stock upon a
      termination of employment, termination of directorship or termination of a
      consultancy arrangement, as applicable, at a cash price per share equal to
      the
      purchase price paid by the Common Stockholder for such Common
      Stock.

    

    5.7 In
      the discretion of the Board or Committee, the Common Stock Agreement may provide
      that the Company shall have the a right of first refusal with respect to the
      Common Stock and a right to repurchase the vested Common Stock upon a
      termination of the Common Stockholder's employment with the Company, the
      termination of the Common Stockholder's consulting arrangement with the Company,
      the termination of the Common Stockholder's service on the Company's Board,
      or
      such other events as the Board or Committee may deem appropriate.

    

    5.8 The
      Board or Committee shall cause a legend or legends to be placed on certificates
      representing shares of Common Stock that are subject to restrictions under
      Common Stock Agreements, which legend or legends shall make appropriate
      reference to the applicable restrictions.

    

    6. Stock
      Option Terms and Conditions

    

    6.1 Consistent
      with the Plan's purpose, Stock Options may be granted to non-employee directors
      of the Company or other persons who are performing or who have been engaged
      to
      perform services of special importance to the management, operation or
      development of the Company.

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    

    6.2 All
      Stock Options granted under the Plan shall be evidenced by agreements which
      shall be subject to applicable provisions of the Plan, and such other provisions
      as the Committee may adopt, including the provisions set forth in paragraphs
      2
      through 11 of this Section 6.

    

    6.3 All
      Stock Options granted hereunder must be granted within ten years from the
      earlier of the date of this Plan is adopted or approved by the Company's
      shareholders.

    

    6.4 No
      Stock Option granted to any employee or 10% Shareholder shall be exercisable
      after the expiration of ten years from the date such NQSO is granted. The
      Committee, in its discretion, may provide that an Option shall be exercisable
      during such ten year period or during any lesser period of time.

     

        The
      Committee may establish installment exercise terms for a Stock Option such
      that
      the NQSO becomes fully exercisable in a series of cumulating portions. If an
      Optionee shall not, in any given installment period, purchase all the Common
      Shares which such Optionee is entitled to purchase within such installment
      period, such Optionee's right to purchase any Common Shares not purchased in
      such installment period shall continue until the expiration or sooner
      termination of such NQSO. The Committee may also accelerate the exercise of
      any
      NQSO. However, no NQSO, or any portion thereof, may be exercisable until thirty
      (30) days following date of grant (“30-Day Holding Period.”).

    

    6.5 A
      Stock Option, or portion thereof, shall be exercised by delivery of (i) a
      written notice of exercise of the Company specifying the number of common shares
      to be purchased, and (ii) payment of the full price of such Common Shares,
      as
      fully set forth in paragraph 6 of this Section 6.

     

        No
      NQSO or installment thereof shall be exercisable except with respect to whole
      shares, and fractional share interests shall be disregarded. Not less than
      100
      Common Shares may be purchased at one time unless the number purchased is the
      total number at the time available for purchase under the NQSO. Until the Common
      Shares represented by an exercised NQSO are issued to an Optionee, he shall
      have
      none of the rights of a shareholder.

    

    6.6 The
      exercise price of a Stock Option, or portion thereof, may be paid:

    

    A. In
      United States dollars, in cash or by cashier's check, certified check, bank
      draft or money order, payable to the order of the Company in an amount equal
      to
      the option price; or

    

    B. At
      the discretion of the Committee, through the delivery of fully paid and
      nonassessable Common Shares, with an aggregate Fair Market Value on the date
      the
      NQSO is exercised equal to the option price, provided such tendered Shares
      have
      been owned by the Optionee for at least one year prior to such exercise;
      or

    

    C. By
      a combination of both A and B above.

     

        The
      Committee shall determine acceptable methods for tendering Common Shares as
      payment upon exercise of a Stock Option and may impose such limitations and
      prohibitions on the use of Common Shares to exercise an NQSO as it deems
      appropriate.

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    

    6.7 With
      the Optionee's consent, the Committee may cancel any Stock Option issued under
      this Plan and issue a new NQSO to such Optionee.

    

    6.8 Except
      by will or the laws of descent and distribution, no right or interest in any
      Stock Option granted under the Plan shall be assignable or transferable, and
      no
      right or interest of any Optionee shall be liable for, or subject to, any lien,
      obligation or liability of the Optionee. Stock Options shall be exercisable
      during the Optionee's lifetime only by the Optionee or the duly appointed legal
      representative of an incompetent Optionee.

    

    6.9 If
      the Optionee shall die while associated with the Company or within three months
      after termination of such association, the personal representative or
      administrator of the Optionee's estate or the person(s) to whom an NQSO granted
      hereunder shall have been validly transferred by such personal representative
      or
      administrator pursuant to the Optionee's will or the laws of descent and
      distribution, shall have the right to exercise the NQSO for one year after
      the
      date of the Optionee's death, to the extent (i) such NQSO was exercisable on
      the
      date of such termination of employment by death, and (ii) such NQSO was not
      exercised, and (iii) the exercise period may not be extended beyond the
      expiration of the term of the Option.

     

        No
      transfer
      of a Stock Option by the will of an Optionee or by the laws of descent and
      distribution shall be effective to bind the Company unless the Company shall
      have been furnished with written notice thereof and an authenticated copy of
      the
      will and/or such other evidence as the Committee may deem necessary to establish
      the validity of the transfer and the acceptance by the transferee or transferee
      of the terms and conditions by such Stock Option.

     

        In
      the event
      of death following termination of the Optionee's association with the Company
      while any portion of an NQSO remains exercisable, the Committee, in its
      discretion, may provide for an extension of the exercise period of up to one
      year after the Optionee's death but not beyond the expiration of the term of
      the
      Stock Option.

    

    6.10 Any
      Optionee who disposes of Common Shares acquired on the exercise of a NQSO by
      sale or exchange either (i) within two years after the date of the grant of
      the
      NQSO under which the stock was acquired, or (ii) within one year after the
      acquisition of such Shares, shall notify the Company of such disposition and
      of
      the amount realized upon such disposition. The transfer of Common Shares may
      also be Common by applicable provisions of the Securities Act of 1933, as
      amended.

    

    7. Adjustments
      or Changes in Capitalization

    

    7.1 In
      the event that the outstanding Common Shares of the Company are hereafter
      changed into or exchanged for a different number or kind of shares or other
      securities of the Company by reason of merger, consolidation, other
      reorganization, recapitalization, reclassification, combination of shares,
      stock
      split-up or stock dividend:

     

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    

    A. Prompt,
      proportionate, equitable, lawful and adequate adjustment shall be made of the
      aggregate number and kind of shares subject to Stock Options which may be
      granted under the Plan, such that the Optionee shall have the right to purchase
      such Common Shares as may be issued in exchange for the Common Shares
      purchasable on exercise of the NQSO had such merger, consolidation, other
      reorganization, recapitalization, reclassification, combination of shares,
      stock
      split-up or stock dividend not taken place;

    

    B. Rights
      under unexercised Stock Options or portions thereof granted prior to any such
      change, both as to the number or kind of shares and the exercise price per
      share, shall be adjusted appropriately, provided that such adjustments shall
      be
      made without change in the total exercise price applicable to the unexercised
      portion of such NQSO's but by an adjustment in the price for each share covered
      by such NQSO's; or

    

    C. Upon
      any dissolution or liquidation of the Company or any merger or combination
      in
      which the Company is not a surviving corporation, each outstanding Stock Option
      granted hereunder shall terminate, but the Optionee shall have the right,
      immediately prior to such dissolution, liquidation, merger or combination,
      to
      exercise his NQSO in whole or in part, to the extent that it shall not have
      been
      exercised, without regard to any installment exercise provisions in such
      NQSO.

    

    7.2 The
      foregoing adjustments and the manner of application of the foregoing provisions
      shall be determined solely by the Committee, whose determination as to what
      adjustments shall be made and the extent thereof, shall be final, binding and
      conclusive. No fractional Shares shall be issued under the Plan on account
      of
      any such adjustments.

    

    8. Merger,
      Consolidation or Tender Offer

    

    8.1 If
      the Company shall be a party to a binding agreement to any merger, consolidation
      or reorganization or sale of substantially all the assets of the Company, each
      outstanding Stock Option shall pertain and apply to the securities and/or
      property which a shareholder of the number of Common Shares of the Company
      subject to the NQSO would be entitled to receive pursuant to such merger,
      consolidation or reorganization or sale of assets.

    

    8.2 In
      the event that:

    

    A. Any
      person other than the Company shall acquire more than 20% of the Common Shares
      of the Company through a tender offer, exchange offer or otherwise;

    

    B. A
      change in the “control” of the Company occurs, as such term is defined in Rule
      405 under the Securities Act of 1933;

    

    C. There
      shall be a sale of all or substantially all of the assets of the
      Company;

     

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    

    any
      then
      outstanding Stock Option held by an Optionee, who is deemed by the Committee
      to
      be a statutory officer (“Insider”) for purposes of Section 16 of the Securities
      Exchange Act of 1934 shall be entitled to receive, subject to any action by
      the
      Committee revoking such an entitlement as provided for below, in lieu of
      exercise of such Stock Option, to the extent that it is then exercisable, a
      cash
      payment in an amount equal to the difference between the aggregate exercise
      price of such NQSO, or portion thereof, and, (i) in the event of an offer or
      similar event, the final offer price per share paid for Common Shares, or such
      lower price as the Committee may determine to conform an option to preserve
      its
      Stock Option status, times the number of Common Shares covered by the NQSO
      or
      portion thereof, or (ii) in the case of an event covered by B or C above, the
      aggregate Fair Market Value of the Common Shares covered by the Stock Option,
      as
      determined by the Committee at such time.

    

    8.3 Any
      payment which the Company is required to make pursuant to paragraph 8.2 of
      this
      Section 8 shall be made within 15 business days, following the event which
      results in the Optionee's right to such payment. In the event of a tender offer
      in which fewer than all the shares which are validly tendered in compliance
      with
      such offer are purchased or exchanged, then only that portion of the shares
      covered by an NQSO as results from multiplying such shares by a fraction, the
      numerator of which is the number of Common Shares acquired pursuant to the
      offer
      and the denominator of which is the number of Common Shares tendered in
      compliance with such offer shall be used to determine the payment thereupon.
      To
      the extent that all or any portion of a Stock Option shall be affected by this
      provision, all or such portion of the NQSO shall be terminated.

    

    8.4 Notwithstanding
      paragraphs 8.1 and 8.3 of this Section 8, the Committee may, by unanimous vote
      and resolution, unilaterally revoke the benefits of the above provisions;
      provided, however, that such vote is taken no later than ten business days
      following public announcement of the intent of an offer or the change of
      control, whichever occurs earlier.

    

    9. Amendment
      and Termination of Plan

    

    9.1 The
      Board may at any time, and from time to time, suspend or terminate the Plan
      in
      whole or in part or amend it from time to time in such respects as the Board
      may
      deem appropriate and in the best interest of the Company.

    

    9.2 No
      amendment, suspension or termination of this Plan shall, without the Optionee's
      consent, alter or impair any of the rights or obligations under any Stock Option
      theretofore granted to him under the Plan.

     

    9.3 The
      Board may amend the Plan, subject to the limitations cited above, in such manner
      as it deems necessary to permit the granting of Stock Options meeting the
      requirements of future amendments or issued regulations, if any, to the
      Code.

    

    9.4 No
      NQSO may be granted during any suspension of the Plan or after termination
      of
      the Plan.

     

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    

    10. Government
      and Other Regulations

    

    10.1 The
      obligation of the Company to issue, transfer and deliver Common Shares for
      Stock
      Options exercised under the Plan shall be subject to all applicable laws,
      regulations, rules, orders and approval which shall then be in effect and
      required by the relevant stock exchanges on which the Common Shares are traded
      and by government entities as set forth below or as the Committee in its sole
      discretion shall deem necessary or advisable. Specifically, in connection with
      the Securities Act of 1933, as amended, upon exercise of any Stock Option,
      the
      Company shall not be required to issue Common Shares unless the Committee has
      received evidence satisfactory to it to the effect that the Optionee will not
      transfer such shares except pursuant to a registration statement in effect
      under
      such Act or unless an opinion of counsel satisfactory to the Company has been
      received by the Company to the effect that such registration is not required.
      Any determination in this connection by the Committee shall be final, binding
      and conclusive. The Company may, but shall in no event be obligated to, take
      any
      other affirmative action in order to cause the exercise of a Stock Option or
      the
      issuance of Common Shares pursuant thereto to comply with any law or regulation
      of any government authority.

    

    11. Miscellaneous
      Provisions

    

    11.1 No
      person shall have any claim or right to be granted a Stock Option or Common
      Stock under the Plan, and the grant of an NQSO or Common Stock under the Plan
      shall not be construed as giving an Optionee or Common Stockholder the right
      to
      be retained by the Company. Furthermore, the Company expressly reserves the
      right at any time to terminate its relationship with an Optionee with or without
      cause, free from any liability, or any claim under the Plan, except as provided
      herein, in an option agreement, or in any agreement between the Company and
      the
      Optionee.

    

    11.2 Any
      expenses of administering this Plan shall be borne by the Company.

    

    11.3 The
      payment received from Optionee from the exercise of Stock Options under the
      Plan
      shall be used for the general corporate purposes of the Company.

    

    11.4 The
      place of administration of the Plan shall be in Florida, United States, and
      the
      validity, construction, interpretation, administration and effect of the Plan
      and of its rules and regulations, and rights relating to the Plan, shall be
      determined solely in accordance with the laws of the State of
      Florida.

    

    11.5 Without
      amending the Plan, grants may be made to persons who are foreign nationals
      or
      employed outside the United States, or both, on such terms and conditions,
      consistent with the Plan's purpose, different from those specified in the Plan
      as may, in the judgment of the Committee, be necessary or desirable to create
      equitable opportunities given differences in tax laws in other
      countries.

     

    11.6 In
      addition to such other rights of indemnification as they may have as members
      of
      the Board or the Committee, the members of the Committee shall be indemnified
      by
      the Company against all costs and expenses reasonably incurred by them in
      connection with any action, suit or proceeding to which they or any of them
      may
      be party by reason of any action taken or failure to act under or in connection
      with the Plan or any Stock Option granted thereunder, and against all amounts
      paid by them in settlement thereof (provided such settlement is approved by
      independent legal counsel selected by the Company) or paid by them in
      satisfaction of a judgment in any such action, suit or proceeding, except a
      judgment based upon a finding of bad faith; provided that upon the institution
      of any such action, suit or proceeding a Committee member shall, in writing,
      give the Company notice thereof and an opportunity, at its own expense, to
      handle and defend the same, with counsel acceptable to the Optionee, before
      such
      Committee member undertakes to handle and defend it on his own
      behalf.

     

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

     

    11.7 Stock
      Options may be granted under this Plan from time to time, in substitution for
      stock options held by employees of other corporations who are about to become
      employees of the Company as the result of a merger or consolidation of the
      employing corporation with the Company or the acquisition by the Company of
      the
      assets of the employing corporation or the acquisition by the Company of stock
      of the employing corporation as a result of which it becomes a subsidiary of
      the
      Company. The terms and conditions of such substitute stock options so granted
      may vary from the terms and conditions set forth in this Plan to such extent
      as
      the Board of Directors of the Company at the time of grant may deem appropriate
      to conform, in whole or in part, to the provisions of the stock options in
      substitution for which they are granted, but no such variations shall be such
      as
      to affect the status of any such substitute stock options as a stock option
      under Section 422A of the Code.

    

    11.8 Notwithstanding
      anything to the contrary in the Plan, if the Committee finds by a majority
      vote,
      after full consideration of the facts presented on behalf of both the Company
      and the Optionee, that the Optionee has been engaged in fraud, embezzlement,
      theft, insider trading in the Company's stock, commission of a felony or proven
      dishonesty in the course of his association with the Company or any subsidiary
      corporation which damaged the Company or any subsidiary corporation, or for
      disclosing trade secrets of the Company or any subsidiary corporation, the
      Optionee shall forfeit all unexercised Stock Options and all exercised NQSO's
      under which the Company has not yet delivered the certificates and which have
      been earlier granted to the Optionee by the Committee. The decision of the
      Committee as to the cause of an Optionee's discharge and the damage done to
      the
      Company shall be final. No decision of the Committee, however, shall affect
      the
      finality of the discharge of such Optionee by the Company or any subsidiary
      corporation in any manner.

     

    12. Written
      Agreement

    

    12.1 Each
      Stock Option granted hereunder shall be embodied in a written Stock Option
      Agreement which shall be subject to the terms and conditions prescribed above
      and shall be signed by the Optionee and by the President or any Vice President
      of the Company, for and in the name and on behalf of the Company. Such Stock
      Option Agreement shall contain such other provisions as the Committee, in its
      discretion shall deem advisable.

     

     

    ATTEST:

    

    /s/
      Claus Wagner Bartak

    Claus
      Wagner Bartak, President

     

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

     

    Number
      of
      Shares:_____                                                                                                                                                                                 Date of Grant: ____

    

    FORM
      OF
      NON-QUALIFIED STOCK OPTION AGREEMENT

    

    AGREEMENT
      made this_____ day of___________ 200__, between _________(the “Optionee”),
      and Red Reef Laboratories International, Inc. (the “Company”).

    

    1. Grant
      of
      Option

     

        The
      Company,
      pursuant to the provisions of the 2007/2008 Non-Qualified Stock Compensation
      Plan (the “Plan”), adopted by the Board of Directors on November 21, 2007, the
      Company hereby grants to the Optionee, subject to the terms and conditions
      set
      forth or incorporated herein, an option to purchase from the Company all or
      any
      part of an aggregate of _______ shares of its $.001 par value Common Stock,
      as such Common Stock is now constituted, at the purchase price of $________
      per
      share. The provisions of the Plan governing the terms and conditions of the
      Option granted hereby are incorporated in full herein by reference.

    

    2. Exercise

     

        The
      Option
      evidenced hereby shall be exercisable in whole or in part on or after ______
      and
      on or before_____________, provided that the cumulative number of shares of
      Common Stock as to which this Option may be exercised (except in the event
      of
      death, retirement, or permanent and total disability, as provided in paragraph
      6.9 of the Plan) shall not exceed the following amounts:

     

                                                        
        Cumulative
      Number                                                                     Prior
      to Date

                                                              
         of
      Shares                                                                         
(Not
      Inclusive
      of)

    

    The
      Option evidenced hereby shall be exercisable by the delivery to and receipt
      by
      the Company of (i) written notice of election to exercise, in the form set
      forth
      in Attachment B hereto, specifying the number of shares to be purchased; (ii)
      accompanied by payment of the full purchase price thereof in cash or certified
      check payable to the order of the Company, or by fully paid and nonassessable
      Common Stock of the Company properly endorsed over to the Company, or by a
      combination thereof, and (iii) by return of this Stock Option Agreement for
      endorsement of exercise by the Company on Schedule I hereof. In the event fully
      paid and nonassessable Common Stock is submitted as whole or partial payment
      for
      shares to be purchased hereunder, such Common Stock will be valued at their
      Fair
      Market Value (as defined in the Plan) on the date such shares received by the
      Company are applied to payment of the exercise price.

     

    3. Transferability

     

        The
      Option
      evidenced hereby is not assignable or transferable by the Optionee other than
      by
      the Optionee's will or by the laws of descent and distribution, as provided
      in
      paragraph 6.9 of the Plan. The Option shall be exercisable only by the Optionee
      during his lifetime.

     

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    

    

    Red
      Reef
      Laboratories International, Inc.

    

    

    By:

    Name:

    Title:

    

    

    ATTEST:                                                                                                                                 

    

    

    ________________________________________

    Secretary

     

        Optionee
      hereby acknowledges receipt of a copy of the Plan, attached hereto and accepts
      this Option subject to each and every term and provision of such Plan. Optionee
      hereby agrees to accept as binding, conclusive and final, all decisions or
      interpretations of the of the Board of Directors administering the Plan on
      any
      questions arising under such Plan. Optionee recognizes that if Optionee's
      employment with the Company or any subsidiary thereof shall be terminated
      without cause, or by the Optionee, prior to completion or satisfactory
      performance by Optionee (except as otherwise provided in paragraph 6 of the
      Plan) all of the Optionee's rights hereunder shall thereupon terminate; and
      that, pursuant to paragraph 6 of the Plan, this Option may not be exercised
      while there is outstanding to Optionee any unexercised Stock Option granted
      to
      Optionee before the date of grant of this Option.

    

    Dated:________       

    

                                                                                                                   

    ______________________________

    Optionee

     

                                                                                                                                                    
      ______________________________

    Print
      Name

     

                                                                                                                                                    
      ______________________________

    Address

     

                                                                                                                                                   
      ______________________________

    Social
      Security No.

     

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

    

     

    NOTICE
      OF EXERCISE

    

    

    (To
      be
      signed only upon exercise of Option)

    

     

    TO:
      Red Reef Laboratories International, Inc.

    

    The
      undersigned, the owner of the attached Option, hereby irrevocably elects to
      exercise the rights to purchase thereunder ________________ (____________)
      shares of Common Stock of Red Reef Laboratories International, Inc. and herewith
      pays for the shares in the manner specified in the Option.  The
      undersigned requests that the certificates for such shares be delivered to
      them
      according to instructions indicated below.  If such shares are not all
      of the shares purchasable under the Option, the undersigned further requests
      that a new option certificate be issued and delivered to the undersigned for
      the
      remaining shares purchasable under the Option.

    

    DATED
      this _____ day of ________, 2007.

    

    

    

    By:_________________________________

    
      	
               

            	 	
              ,
                Optionee

            

    

     

     

    
      
         

      

      
        14

        
          

        

      

      
         

      

    

     

    AFFIDAVIT

    

    I,
      ____________, being an individual residing in the ______________ ("Affiant"),
      make the following affidavit based upon facts known to me about which I could
      competently testify to if so required.

     

        Affiant
      was
      retained by Red Reef Laboratories International, Inc., a Florida corporation,
      ("RRLB") for the following services:

    

    [Summary
      of services rendered]

     

        During
      the
      above-mentioned time, Affiant performed the above described services for RRLB
      or
      its subsidiaries:

     

        The
      services
      provided were not in connection with the offer or sale of securities in a
      capital-raising transaction.  Affiant provided the services with the
      understanding that Affiant would receive compensation for such services,
      possibly including the grant of options to purchase shares of RRLB's common
      stock.

     

        I
      declare
      under the penalty of perjury that the foregoing is true and
      correct.  Executed this _____ day of _____, 2007.

    

    Affiant
–
      (optionee)

    

    

    ___________________________________

    

    STATE
      OF
      FLORIDA                 )

                              
      :ss

    COUNTY
      OF
      __________         )

    

    Before
      me, a notary public of said state, on the ____ day of ____ 2007, personally
      appeared ___________, to me being properly identified and stating that he is
      an
      independent contractor of Red Reef Laboratories International, Inc. (the
      "Company"), who signed the foregoing Affidavit, who being duly sworn,
      acknowledged that he or she signed the same as his voluntary act and deed,
      the
      for the purposes therein expressed, and that the facts stated therein are
      true.

    

    SEAL

    

    ______________________________________________

    Notary
      Public

    

    

    

    
      
         

      

      
        15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]